Holding Pattern: Cannabis Industry Waits for FDA Regulatory Rulemaking

Listen on Apple Podcasts, Google Podcasts, Overcast, Spotify, Stitcher, YouTube.

This Diagnosing Health Care episode dives into the status of the Food and Drug Administration’s (“FDA’s”) plan for regulating cannabis and cannabis-derived products and what actions the agency has taken recently to make progress. The episode features Delia Deschaine and is hosted by Megan Robertson, both attorneys in the firm’s Washington, DC, office.

Here’s a preview of what you’ll hear:

“As we started to learn more about the plant’s therapeutic potential, the interest in developing potential medical therapies that contain cannabinoids has exponentially grown.” – Delia Deschaine, Member of the Firm
“While there's been some positive movement, a lot of barriers still exist for researchers to kind of create that initial threshold comfortable level for FDA safety with respect to these products.” – Megan Robertson, Associate

To learn more about the issues discussed in this episode, read:

FDA Issues Draft Guidance on Cannabis Clinical Research and Sends CBD Enforcement Discretion Guidance to OMB for Review – Health Law Advisor blog post
Federal Courts Say They Will Decide Cases Against CBD Product Manufacturers When the Smoke Clears – Health Law Advisor blog post

About the Diagnosing Health Care Podcast

What health care and life sciences decision-makers need to lead, comply, and compete. The health care industry is full of high-stakes legal, policy, and regulatory obstacles. And significant opportunities for those prepared to act on them. Diagnosing Health Care® delivers the intelligence executives, general counsel, and administrators need to navigate both. Part of the Epstein Becker Green Insights Network.